

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

OVCA433

RRID:CVCL_0475

Type: Cell Line

Proper Citation

RRID:CVCL_0475

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0475

Proper Citation: RRID:CVCL_0475

Description: Cell line OVCA433 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous adenocarcinoma

Defining Citation: [PMID:1536252](#), [PMID:6346879](#), [PMID:7028788](#), [PMID:10318951](#), [PMID:10972993](#), [PMID:11793438](#), [PMID:16382445](#), [PMID:19926575](#), [PMID:22328975](#), [PMID:22585861](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:24434149](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28273451](#), [PMID:30894373](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCA433

Synonyms: OvCa433, OVCA 433, OvCa 433, OVCA-433, OVCA433_Bast, OVCAR-433, OVCAR 433, OVCAR433, SKOV-433, SK-OV-433, OV433

Cross References: BTO:BTO_0002566, EFO:EFO_0006723, MCCL:MCC:0000373, ArrayExpress:E-MTAB-2706, BioSample:SAMN03473291, cancercellines:CVCL_0475, Cell_Model_Passport:SIDM00966, Cosmic:924148, Cosmic:927568, Cosmic:1175882, Cosmic:1524355, Cosmic:1709258, Cosmic-CLP:1480367, DepMap:ACH-002182, EGA:EGAS00001000610, GDSC:1480367, GEO:GSM95433, GEO:GSM711706,

GEO:GSM851931, GEO:GSM1670316, GEO:GSM2474992,
PharmacoDB:OVCA433_1216_2019, PRIDE:PXD003668, PRIDE:PXD030304,
Progenetix:CVCL_0475, Wikidata:Q54936989

ID: CVCL_0475

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260905T182007+0000

Ratings and Alerts

No rating or validation information has been found for OVCA433.

No alerts have been found for OVCA433.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Strauel C, et al. (2026) Matrix metalloproteinase-9 regulates cell adhesion and membrane protrusive activity of ovarian cancer cells. *FEBS open bio*, 16(7), 1414.

Han GH, et al. (2026) Clinical and Functional Characterization of PDE1A as a Wnt/?-Catenin-Linked Biomarker of Progression and Platinum Resistance in Epithelial Ovarian Cancer. *Oncology research*, 34(3), 16.

Elhaw AT, et al. (2026) RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. *Cancer research*, 86(11), 2623.

Wu SK, et al. (2026) Multiscale mechanisms driving tissue rupture by invading cells. *Developmental cell*, 61(4), 787.

Cheng YY, et al. (2025) Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. *Cancer research communications*, 5(7), 1180.

Wang S, et al. (2025) EMSY enhances glycolysis in ovarian cancer cells. *European journal of medical research*, 30(1), 890.

Che X, et al. (2025) TRIM4 modulates the ubiquitin-mediated degradation of hnRNPD and weakens sensitivity to CDK4/6 inhibitor in ovarian cancer. *Frontiers of medicine*, 19(1), 121.

Ho CZ, et al. (2025) Protocol for AI-assisted quantitative analysis and setup of tumor spheroid invasion into tissue. STAR protocols, 6(4), 104140.

Li H, et al. (2024) Functional genetic variants of GEN1 predict overall survival of Chinese epithelial ovarian cancer patients. Journal of translational medicine, 22(1), 577.

Furutake Y, et al. (2024) YAP1 Suppression by ZDHHC7 Is Associated with Ferroptosis Resistance and Poor Prognosis in Ovarian Clear Cell Carcinoma. Molecular cancer therapeutics, 23(11), 1652.

Masi I, et al. (2023) The interaction of β -arrestin1 with talin1 driven by endothelin A receptor as a feature of α 5 β 1 integrin activation in high-grade serous ovarian cancer. Cell death & disease, 14(1), 73.

Jiang W, et al. (2023) A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. International journal of molecular sciences, 24(6).

Chehade H, et al. (2023) MNRR1 is a driver of ovarian cancer progression. Translational oncology, 29, 101623.

Braal CL, et al. (2021) Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs, 81(3), 317.

Lyu T, et al. (2020) SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters. International journal of cancer, 146(6), 1553.